Tags

Type your tag names separated by a space and hit enter

Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.
J Infect Dis. 2005 Sep 01; 192 Suppl 1:S17-21.JI

Abstract

The strategy of decreasing the morbidity and mortality associated with rotavirus gastroenteritis through vaccination is supported by studies demonstrating that wild-type rotavirus infection protects against subsequent rotavirus disease. Primary infection with wild-type rotavirus typically induces homotypic immunity. Vaccination of infants with a multivalent vaccine directed against prevalent rotavirus serotypes is the strategy most likely to provide the broadest degree of protection against rotavirus gastroenteritis. The pentavalent human-bovine reassortant rotavirus vaccine (HBRV) is directed against each of the most prevalent rotavirus serotypes, including G1, G2, G3, G4, and P1. The safety, immunogenicity, and efficacy of different reassortant compositions and formulations of the HBRV have been evaluated in clinical trials. An HBRV dose of > or =8 x 10(6) plaque-forming units has demonstrated 68.8%-76.6% efficacy against any rotavirus gastroenteritis, regardless of severity, and approximatel 100% efficacy against severe rotavirus gastroenteritis for the first rotavirus infection season after vaccination. The HBRV has been generally well tolerated, with no increase in the incidence of fever, vomiting, diarrhea, or behavioral changes among vaccine recipients, compared with placebo recipients, during the 14- and 42-day periods after administration of any dose. Shedding of vaccine strains in feces is uncommon. A large-scale trial is under way to evaluate the efficacy and safety of the manufacturing-scale formulation of pentavalent HBRV.

Authors+Show Affiliations

Merck, West Point, PA 19422, USA. penny_heaton@merck.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16088800

Citation

Heaton, Penny M., et al. "Development of a Pentavalent Rotavirus Vaccine Against Prevalent Serotypes of Rotavirus Gastroenteritis." The Journal of Infectious Diseases, vol. 192 Suppl 1, 2005, pp. S17-21.
Heaton PM, Goveia MG, Miller JM, et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis. 2005;192 Suppl 1:S17-21.
Heaton, P. M., Goveia, M. G., Miller, J. M., Offit, P., & Clark, H. F. (2005). Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. The Journal of Infectious Diseases, 192 Suppl 1, S17-21.
Heaton PM, et al. Development of a Pentavalent Rotavirus Vaccine Against Prevalent Serotypes of Rotavirus Gastroenteritis. J Infect Dis. 2005 Sep 1;192 Suppl 1:S17-21. PubMed PMID: 16088800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. AU - Heaton,Penny M, AU - Goveia,Michelle G, AU - Miller,Jacqueline M, AU - Offit,Paul, AU - Clark,H Fred, PY - 2005/8/10/pubmed PY - 2005/10/14/medline PY - 2005/8/10/entrez SP - S17 EP - 21 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 192 Suppl 1 N2 - The strategy of decreasing the morbidity and mortality associated with rotavirus gastroenteritis through vaccination is supported by studies demonstrating that wild-type rotavirus infection protects against subsequent rotavirus disease. Primary infection with wild-type rotavirus typically induces homotypic immunity. Vaccination of infants with a multivalent vaccine directed against prevalent rotavirus serotypes is the strategy most likely to provide the broadest degree of protection against rotavirus gastroenteritis. The pentavalent human-bovine reassortant rotavirus vaccine (HBRV) is directed against each of the most prevalent rotavirus serotypes, including G1, G2, G3, G4, and P1. The safety, immunogenicity, and efficacy of different reassortant compositions and formulations of the HBRV have been evaluated in clinical trials. An HBRV dose of > or =8 x 10(6) plaque-forming units has demonstrated 68.8%-76.6% efficacy against any rotavirus gastroenteritis, regardless of severity, and approximatel 100% efficacy against severe rotavirus gastroenteritis for the first rotavirus infection season after vaccination. The HBRV has been generally well tolerated, with no increase in the incidence of fever, vomiting, diarrhea, or behavioral changes among vaccine recipients, compared with placebo recipients, during the 14- and 42-day periods after administration of any dose. Shedding of vaccine strains in feces is uncommon. A large-scale trial is under way to evaluate the efficacy and safety of the manufacturing-scale formulation of pentavalent HBRV. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/16088800/Development_of_a_pentavalent_rotavirus_vaccine_against_prevalent_serotypes_of_rotavirus_gastroenteritis_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/431500 DB - PRIME DP - Unbound Medicine ER -